New Hope in Pain Relief: Lilly Advances Non-Opioid Candidate to Phase 2

GHENT, BELGIUM – April 30, 2026 – In a significant development for the millions suffering from chronic pain, pharmaceutical giant Eli Lilly and Company has initiated a Phase 2a clinical trial for CFTX-1554, a promising non-opioid pain candidate. The announcement, made today by Belgian biotech firm Confo Therapeutics, marks a pivotal milestone for the drug, which was discovered using Confo's proprietary technology and could represent a new frontier in treating peripheral pain without the risk of addiction.

The trial will evaluate the efficacy, safety, and tolerability of CFTX-1554 in patients, moving the novel compound one step closer to potentially transforming a field desperate for innovation. This advancement validates the strategic licensing agreement between Confo and Lilly, a partnership poised to tackle one of modern medicine's most pressing challenges.

The Urgent Hunt for a Post-Opioid Painkiller

The landscape of chronic pain management is fraught with peril. For decades, opioids have been a mainstay treatment, but their use is a double-edged sword, offering relief at the cost of severe side effects, including sedation, cognitive impairment, and a high risk of abuse and addiction that has fueled a global public health crisis. Current standard-of-care therapies often provide only partial relief, leaving a vast unmet need for safer, more effective alternatives.

Neuropathic pain, a debilitating type of chronic pain caused by nerve damage and a key target for CFTX-1554, affects an estimated 7-10% of the global population. These patients often find little to no relief from existing medications. The advancement of a non-opioid candidate like CFTX-1554 is therefore not just a scientific achievement but a beacon of hope for individuals whose quality of life has been severely diminished by persistent pain.

The pharmaceutical industry is in a race to develop these alternatives. Vertex Pharmaceutical’s recently approved Suzetrigine, a non-opioid targeting the Nav1.8 channel, signaled a major breakthrough for acute pain and validated new biological targets. Lilly itself is aggressively building a portfolio of non-opioid assets, underscoring a clear industry-wide shift away from traditional pain management strategies.

A Novel Target: The Science Behind CFTX-1554

What sets CFTX-1554 apart is its unique mechanism of action. The compound is a novel antagonist of the angiotensin II type 2 receptor (AT2R). While not a household name, AT2R is a clinically validated target known to play a crucial role in pain signaling pathways. By inhibiting this receptor, CFTX-1554 aims to block pain signals at the peripheral level, before they reach the brain. This approach is designed to provide targeted pain relief while crucially avoiding the centrally mediated side effects—like addiction, euphoria, and sedation—that have made opioids so dangerous.

Targeting AT2R is not an entirely new idea, but previous attempts have stumbled. Novartis's earlier AT2R compound, EMA401, was discontinued in Phase 2 due to toxicity concerns and lackluster efficacy data. However, Confo Therapeutics asserts that CFTX-1554 is a different beast. Thanks to the precision of its discovery platform, the company states its candidate interacts more efficiently with the receptor's binding site, resulting in superior drug-like properties and a potentially cleaner safety profile. This differentiated chemistry may be the key to succeeding where others have failed.

A Biotech's Breakthrough: Confo's Platform Validated

For Confo Therapeutics, a 2015 spin-off from Vrije Universiteit Brussel (VUB) and VIB, this moment is a profound validation of its core technology. The company specializes in drugging G-protein coupled receptors (GPCRs), a notoriously difficult class of drug targets that are embedded in cell membranes and are conformationally unstable. Confo’s proprietary ConfoBodies® platform uses fragments of llama antibodies to lock these GPCRs into a specific, functionally relevant state, making it possible to discover novel drugs against targets previously considered “undruggable.”

The progression of CFTX-1554 into a Lilly-led Phase 2 trial is the first time a candidate discovered with this innovative platform has reached this advanced stage of clinical development. It serves as powerful proof that the technology can yield promising assets attractive to the largest players in the pharmaceutical world.

“The initiation of this study marks a pivotal milestone in Confo’s evolution as the first candidate discovered using our proprietary technology has moved into a Phase 2 clinical trial,” said Cedric Ververken, CEO of Confo Therapeutics, in a statement. “We continue to be impressed by Lilly’s expertise and commitment in progressing CFTX-1554 and we are delighted with the team’s collaborative approach to our valued partnership.”

This success is not a one-off. Confo is leveraging its platform to build a diverse internal pipeline focused on metabolic and endocrine diseases, with programs targeting obesity, hyperparathyroidism, and other conditions, demonstrating the broad applicability of its technology.

Eli Lilly's Strategic Bet on Pain Management

The partnership also sheds light on Eli Lilly's determined strategy in the pain space. Despite past setbacks in pain drug development, the Indianapolis-based pharma giant is doubling down on its commitment to finding non-opioid solutions. The collaboration on CFTX-1554 is a cornerstone of a broader portfolio that includes multiple mid-stage candidates targeting different pain pathways, such as a P2X7 receptor antagonist and a Nav1.8 inhibitor.

The financial terms of the deal, first announced in March 2023, underscore the value Lilly places on Confo’s asset. Confo received a significant $40 million upfront payment and is eligible for up to $590 million in milestone payments for the CFTX-1554 program, plus tiered royalties on potential sales. The agreement even includes the possibility of developing other antibody-based therapeutics against the same target, with Confo retaining a co-investment option for a larger share of future rewards.

This deal, with a potential value exceeding $600 million for the first program alone, is a standout transaction in a sector that has seen approximately $4.5 billion in total strategic alliance value over the past decade. It signals strong confidence from Lilly not only in the CFTX-1554 candidate but also in the underlying science of the AT2R target and the power of Confo's discovery engine. As the Phase 2a trial gets underway, the collaboration represents a convergence of biotech innovation and big pharma's developmental might. The outcome will be watched closely by patients, physicians, and the entire industry, all hoping for a long-awaited breakthrough in the fight against chronic pain.